A5027575142- Bladder and Urothelial Cancer Treatments
- Peptidase Inhibition and Analysis
- Urological Disorders and Treatments
- Urinary and Genital Oncology Studies
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Prostate Cancer Treatment and Research
- Esophageal Cancer Research and Treatment
- PI3K/AKT/mTOR signaling in cancer
- Monoclonal and Polyclonal Antibodies Research
- COVID-19 Clinical Research Studies
- Prostate Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- COVID-19 and healthcare impacts
- Galectins and Cancer Biology
- Testicular diseases and treatments
- SARS-CoV-2 and COVID-19 Research
- Urinary Tract Infections Management
- Bacterial Identification and Susceptibility Testing
- Long-Term Effects of COVID-19
- Urologic and reproductive health conditions
- Tumors and Oncological Cases
- Medical Practices and Rehabilitation
- Sexual function and dysfunction studies
University of Tübingen
2019-2025
Klinik und Poliklinik für Urologie
2025
University Children's Hospital Tübingen
2024-2025
Natural and Medical Sciences Institute
2022
715 Background: The prospective phase 3 study EV-302 demonstrated superiority regarding efficacy of Enfortumab vedotin plus Pembrolizumab (EVP) compared to platinum-based chemotherapy in patients (pts) that received first-line (1L) therapy for metastatic urothelial carcinoma (mUC). Since presentation the data September 2023 EVP was considered a new standard care (SOC) however only approved Europe August 2024. We analyzed and safety outcomes pts treated with outside clinical trials. Methods:...
Interdisciplinary tumor boards (ITB) are essential in optimizing treatment recommendations for metastatic castration-resistant prostate cancer (mCRPC) by incorporating oncology guidelines, clinical trials, and patient-specific factors to ensure individualized care. This study examines parameters that influence ITB recommendations, evaluates their adherence assesses impact on patient survival. In a retrospective analysis, data from 187 mCRPC patients discussed at an tertiary care center 2018...
e16548 Background: Patients with terminal renal failure (GFR <30 ml/min or dialysis), poor performance status (ECOG ≥2), and/or age ≥80 are often excluded underrepresented in pivotal clinical trials evaluating enfortumab vedotin and pembrolizumab (EV/P) as first-line (1L) treatment metastatic urothelial carcinoma (mUC). Consequently, data on safety efficacy these populations limited. This study evaluates EV/P outcomes this high-risk group. Methods: multicenter, real-world, retrospective...
Background: The selection of suitable patients for the surgical treatment benign prostatic obstruction (BPO) is a challenge in persons ≥75 years age. Methods: After systematic literature search PubMed, 22 articles were included this review. Clinical and functional parameters evaluated statistically. Results: mean age was ≥79 years. duration postoperative catheterization ranged between 2 (d) (ThuLEP, thulium laser enucleation prostate) 4.4 days (TURP, transurethral resection prostate)....
Bone formation markers c-terminal telopeptide of type I collagen (1CTP) and peptides n-terminal propeptide procollagen (P1NP) were reported to be increased in patients with prostate cancer (PC) bone metastases. The objective the presented study was investigate utility serum 1CTP P1NP values diagnosis metastases predicting oncological outcome PC.In total, samples 186 included retrospectively including 53 (28.50%) benign prostatic hyperplasia (BPH) 133 (71.50%) PC-patients. group PC consisted...
Little is known about the antimicrobial resistance (AMR) status of uropathogens in Western Africa. We performed a retrospective evaluation urine cultures collected from rural Margret Marquart Catholic Hospital, Kpando, Ghana during time period October 2019–December 2021. Urine samples 348 patients (median age 40 years, 52.6% male) were examined. Of these, 125 (35.9%) showed either fungal or bacterial growth, including Escherichia coli 48 (38.4%), Candida species (spp.) 29 (23.2%), Klebsiella...
553 Background: Enfortumab vedotin (EV) is an antibody drug conjugate targeting Nectin-4. It was approved by EMA/FDA in patients (pts) with metastatic/ locally advanced urothelial cancer post platinum and immune check point inhibitors following the results of EV-301 trial. We report updated efficacy safety data EV a large European cohort real-world pts (GUARDIANS consortium) treated hospitals private practices. Methods: Retrospective were collected from 25 German Swiss practices for who...
Background: The retzius-sparing approach for robotic-assisted radical prostatectomy (RARP) has been increasingly adopted. Symptomatic lymphoceles are a widespread complication of RARP with pelvic lymph node dissection. Here, we present new technique, the peritoneal purse-string suture (PPSS), that seems to reduce rate symptomatic following extended dissection (ePLND). Methods: and bilateral lymphadenectomy performed through three separate openings. PPSS uses single in way similar suture;...
Improvements in laparoscopic partial nephrectomy (LPN) order to minimize perioperative warm ischemia time (WIT), complications, and consequently patient outcome are desirable. Veriset™ is a ready-to-use hemostatic patch of absorbable oxidized cellulose hydrogel components that has earlier been implemented vascular hepatic surgery. We report our experience using this device LPN.Patients with solitary malignant renal mass suspicious for cancer underwent LPN either the use (n = 40) or...
<b><i>Introduction:</i></b> There is still a lack of availability high-quality multiparametric magnetic resonance imaging (mpMRI) interpreted by experienced uro-radiologists to rule out clinically significant PC (csPC). Consequently, we developed new method based on computed tomographic ultrasound (US) supported artificial neural network analysis (ANNA). <b><i>Methods:</i></b> Two hundred and two consecutive patients with visible mpMRI lesions...
e16562 Background: Enfortumab vedotin (EV) is an antibody drug conjugate targeting Nectin-4. It was approved by EMA/FDA in patients (pts) with metastatic/ locally advanced urothelial cancer post platinum and immune check point inhibitors (ICI) following the results of EV-301 trial. We report updated efficacy data EV a large European cohort real-world pts (GUARDIANS consortium) treated hospitals private practices. Methods: Retrospective were collected from 25 German Swiss practices for who...
Background: The purpose of this study was to retrospectively analyze the diagnostic accuracy magnetic resonance imaging (MRI) examinations scrotum in comparison with standard ultrasound (US) and histopathology. Methods: A retrospective multi-center analysis MRI performed between 06/2008 04/2021 conducted. Results: total n = 113 patients were included. 53 histopathologies available, 52.8% malignant 50.9% benign findings. Related histopathology, true negative, false positive, positive 4.1%,...
<p>Supplementary Figure 1. Expression of membranous NECTIN-4 in UC histology subtypes PRIM (A) and MET (B). (C) depicts differential expression during metastatic spread. Intergroup comparison was calculated by non-parametric Kruskal-Wallis test.</p>
<p>Supplementary Table 1. Clinico-pathological characteristics of the UC progression PRIM-MET study cohort. BRA=brain metastasis; HEP=hepatic LYM=non-locoregionary lymph node OSS=bone OTH= metastasis at other locations including soft tissue; PER=peritoneal PUL=pulmonary metastasis.</p>
<p>Supplementary Table 2. Baseline characteristics of the multicenter EV cohort.</p>
<p>Supplementary Table 1. Clinico-pathological characteristics of the UC progression PRIM-MET study cohort. BRA=brain metastasis; HEP=hepatic LYM=non-locoregionary lymph node OSS=bone OTH= metastasis at other locations including soft tissue; PER=peritoneal PUL=pulmonary metastasis.</p>
<p>Supplementary Table 2. Baseline characteristics of the multicenter EV cohort.</p>
<p>Supplementary Figure 1. Expression of membranous NECTIN-4 in UC histology subtypes PRIM (A) and MET (B). (C) depicts differential expression during metastatic spread. Intergroup comparison was calculated by non-parametric Kruskal-Wallis test.</p>